title: Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
abstract: Clopidogrel pharmacotherapy is associated with substantial interindividual variability in clinical response, which can translate into an increased risk of adverse outcomes. Clopidogrel, a recognized substrate of hepatic carboxylesterase 1 (CES1), undergoes extensive hydrolytic metabolism in the liver. Significant interindividual variability in the expression and activity of CES1 exists, which is attributed to both genetic and environmental factors. We determined whether CES1 inhibition and CES1 genetic polymorphisms would significantly influence the biotransformation of clopidogrel and alter the formation of the active metabolite. Coincubation of clopidogrel with the CES1 inhibitor bis(4-nitrophenyl) phosphate in human liver s9 fractions significantly increased the concentrations of clopidogrel, 2-oxo-clopidogrel, and clopidogrel active metabolite, while the concentrations of all formed carboxylate metabolites were significantly decreased. As anticipated, clopidogrel and 2-oxo-clopidogrel were efficiently hydrolyzed by the cell s9 fractions prepared from wild-type CES1 transfected cells. The enzymatic activity of the CES1 variants G143E and D260fs were completely impaired in terms of catalyzing the hydrolysis of clopidogrel and 2-oxo-clopidogrel. However, the natural variants G18V, S82L, and A269S failed to produce any significant effect on CES1-mediated hydrolysis of clopidogrel or 2-oxo-clopidogrel. In summary, deficient CES1 catalytic activity resulting from CES1 inhibition or CES1 genetic variation may be associated with higher plasma concentrations of clopidogrel-active metabolite, and hence may enhance antiplatelet activity. Additionally, CES1 genetic variants have the potential to serve as a biomarker to predict clopidogrel response and individualize clopidogrel dosing regimens in clinical practice.
authors.affiliation: Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, USA.
authors.forename: Hao-Jie
authors.initials: HJ
authors.lastname: Zhu
authors.forename: Xinwen
authors.initials: X
authors.lastname: Wang
authors.forename: Brian E
authors.initials: BE
authors.lastname: Gawronski
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Brinda
authors.forename: Dominick J
authors.initials: DJ
authors.lastname: Angiolillo
authors.forename: John S
authors.initials: JS
authors.lastname: Markowitz
mesh_terms: D001711:Biotransformation; D002265:Carboxylic Ester Hydrolases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D002460:Cell Line; D000077144:Clopidogrel; D006801:Humans; D006868:Hydrolysis; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009596:Nitrophenols / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011110:Polymorphism, Genetic; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics
chemical_list: D009596:Nitrophenols; D010975:Platelet Aggregation Inhibitors; C540904:2-oxo-clopidogrel; C002887:bis(4-nitrophenyl)phosphate; D000077144:Clopidogrel; D002265:Carboxylic Ester Hydrolases; C474609:CES1 protein, human; D013988:Ticlopidine